Cervical cancer: First 3-D image of an HPV oncoprotein

February 15, 2013

(Medical Xpress)—For the first time, researchers from the Laboratoire biotechnologie et signalisation cellulaire at the Strasbourg-based Ecole supérieure de biotechnologie (CNRS/Université de Strasbourg) and Institut de génétique et de biologie moléculaire et cellulaire (CNRS/Université de Strasbourg/Inserm) have solved the three-dimensional structure of an important oncoprotein involved in cell proliferation and in the development of the human papilloma virus (HPV). Type 16 (HPV 16), which causes cervical cancer, is the most dangerous of human papilloma viruses. This work, published in Science on 8 February 2013, should make it possible to identify and improve medication to block the protein and prevent it from causing tumors.

is one of the most common cancers in the world, ranking second in terms of mortality among women. It is caused by so-called "high-risk" human papilloma viruses (HPV), of which type 16 (HPV 16) is the most dangerous. After infecting a healthy cell, HPV must stimulate it to multiply in order to reproduce itself. The E6 and E7 cause and the development of cervical cancer, which is why they are known as "oncoproteins".

For the first time, researcher Gilles Travé and his team at the laboratoire Biotechnologie et signalisation cellulaire (CNRS/University of Strasbourg) working in collaboration with researchers led by Jean Cavarelli and Bruno Keiffer of the Institut de génétique et de biologie moléculaire et cellulaire (CNRS/University of Strasbourg/) have solved the three-dimensional structures of E6 proteins in type-16 and its type 1 bovine equivalent (BPV 1). The same researchers had already solved the structure of E6 in HPV 16 in 2012, but this time the E6 proteins have been "caught" in the process of capturing target . The complete structure of an E6 protein—which is very tricky to produce in the laboratory—had remained unsolved for almost 30 years.

Success depended on two factors: the development of methods for isolating protein E6 as well as the use of nuclear magnetic resonance (NMR) and crystallography techniques. Having dealt with various aggregation and purification problems, the researchers succeeded in obtaining protein E6. The challenge then was to keep it in its folded form (so as to preserve its ability to organize itself and thus be biologically active). NMR and crystallography data made it possible to determine the structure of the E6 protein and obtain a high-resolution 3D "photograph".The three-dimensional structure of the E6 protein capturing its target reveals the exact molecular mechanism of its carcinogenic activity. It also explains the protein's remarkable ability to act as a viral terrorist and hijack many of the functions of the infected cell. This breakthrough is crucial for cervical cancer treatment, as it should make it possible to identify and improve medication to prevent the from causing tumors.

Explore further: Cervical cancer and pre-cancer cervical growths require single HPV protein

More information: Zanier, K. et al. Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. Science, 8 February 2013, Vol. 339 no. 6120 pp. 694-698, DOI: 10.1126/science.1229934.

Related Stories

Cervical cancer and pre-cancer cervical growths require single HPV protein

September 17, 2012
(Medical Xpress)—Human papillomavirus (HPV) has long been implicated in cervical cancer, but details of how it happens have remained a mystery. Now researchers at the University of Wisconsin-Madison have found that a single ...

Rating HPV biomarkers in head, neck cancers: Combinations work better than viral DNA in tumors alone

September 18, 2012
Not all head and neck cancers are created equal. Those started by infection with the human papillomavirus are less often fatal than those with other causes, such as smoking. Detection of a reliable fingerprint for HPV could ...

Scientists find cancer-causing virus in the brain, potential connection to epilepsy

January 24, 2013
Researchers at Shriner's Hospital Pediatric Research Center at the Temple University School of Medicine, and the University of Pennsylvania have evidence linking the human papillomavirus 16 (HPV16) – the most common cause ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.